Eli Lilly and Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up ...
President Trump said he has decided on who he plans to nominate to replace Federal Reserve Chair Jerome Powell, but didn't ...
The WHO issued guideline on the use of GLP-1 therapies for obesity, conditionally recommending them as part of long-term ...
New WHO guidance calls for a worldwide obesity treatment “ecosystem” to ensure that GLP-1 weight-loss drugs are used fairly ...
Omeros Corporation (Nasdaq: OMER) today announced the closing of the asset sale and licensing transaction between Omeros and Novo Nordisk for the candidate drug zaltenibart (formerly OMS906).
Lilly's Zepbound price cuts ranged from $50 to $100, depending on the dosage, for consumers who pay cash via the drugmaker's ...
A promising obesity and diabetes drug stumbles in Alzheimer's trials, rattling markets. Did investors overreact, or is this a ...
In the early November announcement of its agreement with the government, Lilly pledged to reduce the self-pay price of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback